Abivax Stock Plunges on Cancer Signal in Ulcerative Colitis Trial
Abivax stock fell as much as 40% on Tuesday after the French biotech released late-stage trial data for its ulcerative colitis drug that showed strong efficacy results alongside cancer cases in the higher-dose group, rattling investors and prompting an analyst downgrade. I